New triple therapy shows promise for tough rectal cancer
NCT ID NCT07509424
First seen Apr 03, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study tests a new treatment plan for people with advanced rectal cancer that has a protein called HER2. Patients first get a short course of radiation, then a combination of three drugs: disitamab vedotin, sintilimab, and capecitabine. The goal is to see if this approach can make the cancer disappear completely before surgery. About 29 adults aged 18 to 75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.